Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage

Background and Purpose: Intracranial hemorrhage has been observed in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19), but the clinical, imaging, and pathophysiological features of intracranial bleeding during COVID-19 infection remain poorly characterized. This study describes clinical and imaging characteristics of patients with COVID-19 infection who presented with intracranial bleeding in a European multicenter cohort. Methods: This is a multicenter retrospective, observational case series including 18 consecutive patients with COVID-19 infection and intracranial hemorrhage. Data were collected from February to May 2020 at five designated European special care centers for COVID-19. The diagnosis of COVID-19 was based on laboratory-confirmed diagnosis of SARS-CoV-2. Intracranial bleeding was diagnosed on computed tomography (CT) of the brain within one month of the date of COVID-19 diagnosis. The clinical, laboratory, radiologic, and pathologic findings, therapy and outcomes in COVID-19 patients presenting with intracranial bleeding were analyzed. Results: Eighteen patients had evidence of acute intracranial bleeding within 11 days (IQR 9–29) of admission. Six patients had parenchymal hemorrhage (33.3%), 11 had subarachnoid hemorrhage (SAH) (61.1%), and one patient had subdural hemorrhage (5.6%). Three patients presented with intraventricular hemorrhage (IVH) (16.7%). Conclusion: This study represents the largest case series of patients with intracranial hemorrhage diagnosed with COVID-19 based on key European countries with geospatial hotspots of SARS-CoV-2. Isolated SAH along the convexity may be a predominant bleeding manifestation and may occur in a late temporal course of severe COVID-19.

[1]  Bernd Weissmuller,et al.  Trials , 2020, Israelpolitik.

[2]  M. Versino,et al.  Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient , 2020, Journal of Neurology.

[3]  R. Garg,et al.  Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline , 2020, Journal of the Neurological Sciences.

[4]  L. Saba,et al.  Imaging of Neurologic Disease in Hospitalized Patients with COVID-19: An Italian Multicenter Retrospective Observational Study , 2020, Radiology.

[5]  H. Kamel,et al.  Risk of Ischemic Stroke in Patients with Covid-19 versus Patients with Influenza , 2020, medRxiv.

[6]  M. Castillo,et al.  Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection , 2020, American Journal of Neuroradiology.

[7]  Julie G. Burel,et al.  Mechanical Thrombectomy for Acute Ischemic Stroke Amid the COVID-19 Outbreak , 2020, Stroke.

[8]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[9]  N. O'Connell,et al.  COVID19 coagulopathy in Caucasian patients , 2020, British journal of haematology.

[10]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[11]  E. Andrès,et al.  Immune Thrombocytopenic Purpura in a Patient with Covid-19 , 2020, The New England journal of medicine.

[12]  B. Liang,et al.  Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis , 2020, Journal of Infection.

[13]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[14]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[15]  G. Lippi,et al.  D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.

[16]  L. Mao,et al.  Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists , 2020, Stroke and vascular neurology.

[17]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[18]  Amaryllis Mavragani,et al.  Tracking COVID-19 in Europe: Infodemiology Approach , 2020, JMIR public health and surveillance.

[19]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[20]  A. Sweidan,et al.  Coagulopathy reversal in intracerebral haemorrhage , 2020, Stroke & Vascular Neurology.

[21]  P. Coyle,et al.  Central Nervous System Vasculitis due to Infection. , 2019, Neurologic clinics.

[22]  S. Blackburn,et al.  Endothelial Cell Dysfunction and Injury in Subarachnoid Hemorrhage , 2018, Molecular Neurobiology.

[23]  E. Fan,et al.  Intracranial hemorrhage in adults on ECMO , 2018, Perfusion.

[24]  R. Gerraty,et al.  Cerebral amyloid angiopathy: Review of clinico‐radiological features and mimics , 2018, Journal of medical imaging and radiation oncology.

[25]  T. Kiehl,et al.  Critical Illness–Associated Cerebral Microbleeds , 2017, Stroke.

[26]  O. Naggara,et al.  Primary Angiitis of the Central Nervous System: Magnetic Resonance Imaging Spectrum of Parenchymal, Meningeal, and Vascular Lesions at Baseline , 2017, Stroke.

[27]  M. Barboza,et al.  Reversible cerebral vasoconstriction syndrome and nonaneurysmal subarachnoid hemorrhage. , 2014, Journal of vascular and interventional neurology.

[28]  G. Hunder,et al.  Adult primary central nervous system vasculitis , 2012, The Lancet.

[29]  S. Zeiler,et al.  Diagnosing CNS Vasculitis: The Case Against Empiric Treatment , 2012, The neurologist.

[30]  G. Hunder,et al.  Adult primary central nervous system vasculitis: an update , 2012, Current opinion in rheumatology.

[31]  G. Hunder,et al.  Primary central nervous system vasculitis presenting with intracranial hemorrhage. , 2011, Arthritis and rheumatism.

[32]  V. Larrue,et al.  Isolated Acute Nontraumatic Cortical Subarachnoid Hemorrhage , 2010, American Journal of Neuroradiology.

[33]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2010, Stroke.

[34]  J. Penninger,et al.  SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS , 2009, European journal of clinical investigation.

[35]  A. Adebajo,et al.  Virus-induced vasculitis , 2008, Current rheumatology reports.

[36]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[37]  R. Jain,et al.  Varicella-zoster vasculitis presenting with intracranial hemorrhage. , 2003, AJNR. American journal of neuroradiology.

[38]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[39]  A. Ropper,et al.  Intracranial pressure monitoring in comatose patients with cerebral hemorrhage. , 1984, Archives of neurology.

[40]  C. E. WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .

[41]  J. Broderick,et al.  Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. , 2017, Stroke.

[42]  R. Grossman,et al.  Cerebral vasculitis: MR imaging and angiographic correlation. , 1992, Radiology.